Why Chemists Are Striking

India's pharmaceutical retail sector faces a nationwide shutdown on May 20 as the All India Organisation of Chemists and Druggists (AIOCD) protests. Representing over 1.24 million chemists and distributors, the AIOCD is challenging the rapid growth of online pharmacies and their aggressive discounting. The core issue is the gap between new digital healthcare methods and current regulations, which threatens traditional pharmacies and raises public health concerns.

Health Risks and Regulatory Loopholes

The AIOCD points to the 'unregulated functioning' of e-pharmacies as a major concern. They argue that notification G.S.R. 817(E) allows dispensing with weak prescription checks, risking misuse of antibiotics and controlled drugs. The group is especially worried about AI-generated fake prescriptions potentially worsening antimicrobial resistance (AMR). The AIOCD also wants G.S.R. 220(E), a COVID-era rule, withdrawn. They claim it has weakened Drug Rule 65, letting online platforms bypass compliance. This lack of clear rules favors digital players and disadvantages traditional pharmacies.

Market Impact and Small Retailers

The strike highlights economic challenges for India's many independent chemists, who hold about 54% of the retail pharmacy market. While large chains and online pharmacies grow, smaller shops often struggle with low profits, especially in rural areas. The AIOCD claims aggressive discounting by larger companies makes local businesses unsustainable. This is a clash between digital platforms seeking growth and the established network that still handles most medicine sales outside big cities. Key e-pharmacies include Tata 1mg (31% share in early 2026), Apollo 24|7 (28%), PharmEasy (15%), and Netmeds (7%). Some, like PharmEasy (API Holdings), report losses despite revenues of ₹5,872.16 Cr in FY25. Apollo Hospitals, however, shows a different financial picture, with INR 242.15 billion revenue and INR 18.02 billion profit recently, and a P/E ratio near 61.86 in May 2026.

Safety Concerns and Past Disruptions

Critics say e-pharmacies' use of G.S.R. 817(E) and G.S.R. 220(E) is a key weakness. They argue these rules, meant as temporary or drafts, are being exploited to create a 'legal grey area,' harming drug safety and regulation. This raises risks of selling fake, sub-standard, or counterfeit medicines, and makes it too easy to get habit-forming drugs. The unchecked sale of antibiotics also fuels antimicrobial resistance (AMR), a serious public health issue previously highlighted by the Prime Minister. Past chemists' strikes in 2015, 2017, and 2020 show how disruption can occur when retailers feel their jobs and medicine safety are at risk. The AIOCD's warning of continued action shows how serious retailers are about these concerns.

Future of Pharmacy Distribution

Regulators face a crucial decision as the strike looms. India's pharmaceutical market, predicted to hit $79.74 billion by 2031, relies on both traditional and online channels. Online pharmacies are projected to grow 9.45% annually, but this requires clear rules. The AIOCD's demands for specific rule withdrawals and fair competition aim to shape new regulations. If concerns aren't met, ongoing disruptions could affect patient access, especially in smaller areas. While the healthcare sector showed strength recently, with Nifty Pharma rising 0.22% on May 11, 2026, against a Nifty 50 decline, a prolonged strike could test this resilience and impact India's digital health future.